Tag: Eli Lilly

7/24/2015

Taking stock of new Alzheimer’s drug coverage: A “landmark breakthrough” that offers no “clinically apparent benefit”

Blog

Opinions on other issues in news, journals, PR, advertising, marketing

@HealthNewsRevu

Retweet on TwitterHealthNewsReview.org Retweeted
NBCCStopBCNational Breast Cancer Coalition@NBCCStopBC·

A lot of interesting workshops are happening now at the #NBCCSummit! @garyschwitzer, the publisher of @HealthNewsRevu, is discussing new cancer research news. #BeBold

Reply on Twitter 1520768892888567810Retweet on Twitter 15207688928885678101Like on Twitter 15207688928885678103Twitter 1520768892888567810
HealthNewsRevuHealthNewsReview.org@HealthNewsRevu·

Take all the issues enmeshed in any cancer screening story and amplify it with the liquid biopsy issue. @AP's ⁦@CarlaKJohnson⁩. did a solid job here. https://apnews.com/article/science-business-health-hodgkin-lymphoma-oregon-ca899bb9c4c7f1859d4e9ce16a1cf78d

Reply on Twitter 1516522980385472513Retweet on Twitter 1516522980385472513Like on Twitter 15165229803854725134Twitter 1516522980385472513
HealthNewsRevuHealthNewsReview.org@HealthNewsRevu·

Come on, NY Times; you must do better than this. Important research doesn’t need hype and the “breaking news” BS doesn’t help readers or patients. https://www.healthnewsreview.org/2022/03/nyt-proclaims-breaking-news/

Reply on Twitter 1506684595651035136Retweet on Twitter 15066845956510351361Like on Twitter 15066845956510351366Twitter 1506684595651035136
View More

Categories

View More

Tags